Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 18/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22568444 | 0.89 | ESR2 (0.50) | ESR2IDO1CYP2C9CYP2C8TDO2 | |
| SCHEMBL21035078 | 0.89 | IDO1 (0.53) | IDO1CYP2C9CYP2C8TDO2CHRNA1 | |
| SCHEMBL22568428 | 0.87 | ESR2 (0.48) | ESR2IDO1CYP2C9CYP2C8TDO2 | |
| SCHEMBL22270940 | 0.86 | IDO1 (0.44) | IDO1CYP2C9CYP2C8TDO2CHRNA1 | |
| SCHEMBL22387541 | 0.86 | IDO1 (0.44) | IDO1CYP2C9CYP2C8TDO2CHRNA1 | |
| SCHEMBL22568421 | 0.85 | ESR2 (0.47) | ESR2IDO1CYP2C9CYP2C8TDO2 | |
| SCHEMBL18826850 | 0.85 | ESR2 (0.53) | ESR2JAK2JAK1 | |
| SCHEMBL22568435 | 0.84 | ESR2 (0.49) | ESR2JAK2JAK1 | |
| SCHEMBL22274820 | 0.83 | ESR2 (0.51) | ESR2IDO1CYP3A4JAK2JAK1 | |
| SCHEMBL22568188 | 0.83 | ESR2 (0.47) | ESR2IDO1CYP2C9CYP2C8TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | ANGEX PHARMACEUTICAL, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11111230-B2 | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200331887-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200239464-A1 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | ANGEX PHARMACEUTICAL, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2019158051-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | 中国科学院上海有机化学研究所 | 2019-08-22 | — | — | WO | disclosed |
| WO-2019141153-A1 | INDOLAMINE 2,3-DIOXYGENASE INHIBITOR AND USE THEREOF | 杭州阿诺生物医药科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-3452029-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | Bristol-Myers Squibb Company (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192840-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331887-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE | IDO1, IDO2, INMT | ESR2 2748/4885IDO1 1/4885CYP2C9 154/4885 |
| US-20210047290-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | IDO1, IDO2, TPH1 | ESR2 879/4885IDO1 1/4885CYP2C9 258/4885 |
| US-10544099-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | ESR2 2060/4885IDO1 1/4885CYP2C9 2175/4885 |
| US-11111230-B2 | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | IDO1, IDO2, INMT | ESR2 2748/4885IDO1 1/4885CYP2C9 154/4885 |
| US-20200239464-A1 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | IDO1, IDO2, INMT | ESR2 3922/4885IDO1 1/4885CYP2C9 2874/4885 |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | ESR2 2060/4885IDO1 1/4885CYP2C9 2175/4885 |
| US-11180497-B2 | Cyclic compounds as immunomodulating agents | IDO1, IDO2, INMT | ESR2 4200/4885IDO1 1/4885CYP2C9 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.